Hartfalen

EXPANDed: bij 73% verbetert tricuspidalisinsufficiëntie binnen 30 dagen na M-TEER — zonder directe TR-interventie

Pooled analyse van de EXPAND- en EXPAND G4-studies bij 160 patiënten met mitralis- en tricuspidalisinsufficiëntie die mitraal transcatheter edge-to-edge repair (M-TEER, MitraClip) ondergingen en GEEN directe TR-interventie kregen.

Echocardiografische beoordeling door onafhankelijk corelab. Op 30 dagen verbeterde 73% (n=116) naar ≤matige TR; 28% (n=44) bleef ≥ernstig. De ≤matige TR-groep had minder atriumfibrilleren (68% vs 89%, p=0,009), iets lagere LVEF (49% vs 56%, p=0,07) en grotere LV-dimensies (LVEDV 137,5 vs 107,9 mL, p=0,01).

TR-reductie hield na 1 jaar stand bij 86% van de ≤matige groep; 45% van de ≥ernstig-groep verbeterde alsnog. Significante en grotere verbetering van NYHA-klasse en KCCQ-OS-score in de ≤matige groep. 1-jaars sterfte numeriek lager bij ≤matige TR (12,4% vs 22,3%; HR 1,92; p=0,16).

LV-dilatatie en lagere LVEF voorspelden TR-verbetering — relevant voor selectie van patiënten die mogelijk geen aanvullende TR-ingreep nodig hebben.

Abstract (original)

BACKGROUND: Transcatheter therapies offer new treatment options for patients with both mitral regurgitation (MR) and tricuspid regurgitation (TR). However, the optimal treatment pathway in patients with combined MR and TR is not completely understood. AIMS: This analysis evaluated the natural TR progression after mitral transcatheter edge-to-edge repair (MTEER) with the MitraClip System in patients with MR and TR from the EXPANDed studies. METHODS: EXPANDed is a pooled cohort from the EXPAND and EXPAND G4 studies. This study includes patients who had severe TR, achieved procedural success with MTEER, and received no direct TR intervention. Echocardiographic assessments were performed independently by echo core lab. Baseline characteristics, 1-year outcomes, and associations with TR improvement were reported based on 30-day TR severity following MTEER. RESULTS: Of those with evaluable TR data at 30 days (N = 160), 73% (N = 116) improved to ≤moderate TR, while 28% (N = 44) had ≥severe TR. The ≤moderate TR group had a lower prevalence of atrial fibrillation (68% vs 89%, P = .009), numerically lower LV ejection fraction (49% vs 56%, P = .07), and larger LV dimensions (LVEDV: 137.5 ± 73.4 vs 107.9 ± 44.8 ml, P = .01). TR reduction was sustained in 86% of ≤moderate TR patients, while 45% of ≥severe TR patients improved to ≤moderate at 1 year. In the ≤moderate TR group, significant and larger improvements in NYHA functional class (P < .0001) and KCCQ-OS score (Δ = + 30.6 ± 25.7, P < .0001) were observed through 1 year. One-year mortality was numerically lower in the ≤moderate TR group (12.4% vs 22.3%) though not statistically significant (HR = 1.92 [.77, 4.79], P = .16). Lower LVEF and larger baseline LV size were associated with TR improvement post-MTEER. CONCLUSIONS: Early TR improvement to ≤moderate was observed in almost 3/4 of the population and was associated with significant symptomatic relief. Patients with both severe MR and TR, particularly those with LV dilation, may experience TR improvement following MTEER.

Dit artikel is een samenvatting van een publicatie in ESC heart failure. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.

Lees het volledige artikel

DOI: 10.1093/eschf/xvag108

Lid worden van HartVaat.nl?

Gratis — en we stemmen het nieuws en de literatuur af op uw vakgebied.

Maak een gratis account